Targeted Genetics partnership strategy is to advance gene delivery as a new approach to treating today's most significant and intractable diseases by colaborating with leaders in key therapeutic areas and innovation technologies. By combining valuable expertise and other assets of established organizations, we intend to accelerate the availability of new product opportunities that will ultimately benefit patients and partners alike.
Through our partnerships, we are leading the charge to establish gene-based therapies as a proven class of therapeutics that will find important use as a new weapon in the war against disease. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and our partnership goal is to discover gene-based therapies that deliver the DNA sequences encoding proteins and antibodies are the next step in the evolution of biopharmaceuticals.
We offer our partners:
- Leading scientific expertise in multiple gene delivery systems to maximize product opportunities – broadest gene delivery technology platforms in the field;
- In-depth knowledge base in quality assurance, quality control, general research, regulatory affairs and clinical affairs
- Unmatched AAV manufacturing capabilities;
- Well-protected intellectual property portfolio;
- A Strong leadership team and collaborative culture needed for mutually beneficial partnerships.
|
